Abstract 784P
Background
The incidence of HPV integration is increased during the disease progression from precancerous lesions to carcinoma, and HPV integration is reputed as a key effect to escape eliminations from the host cells. Although HPV integration is identified in HPV-related carcinoma, the mechanisms underlying HPV carcinogenesis remain unclear.
Methods
Here, 6768 HPV integration sites from cervical carcinoma (CESC) and 470 from head & neck carcinoma (HNSC), high-through chromosome conformation capture (Hi-C), ChIP-seq, ChIP-PCR and RNA-seq were analyzed to identify the HPV integration characteristics in HPV-host interactions. Manual HPV-integration cells, an HPV integration mouse model (K14-HPV, FVB/N), and CRISPR-Cas9 knock-out cells were performed to demonstrate the chromatin remolding between universal stripe factors (USFs) and super-enhancers.
Results
In CESC and HNSC, USF motifs were enriched in HPV integration sites and integrated HPV-host interaction regions. In addition, HPV integration sites and integrated HPV-host interaction regions marked increased chromatin accessibility (ATAC-seq) and super-enhancer elements (H3K27ac, H3K4me1, and H3K4me3), with USF motifs enrichment in these regions. By dividing the tumor samples according to HPV status, USF genes were found to be upregulated in CESC and HNSC, which could be validated by tumor samples, manual HPV-integration cells, and the K14-HPV integration mouse model. Furthermore, three-dimensional chromatin analyses reveal the chromatin interactions between USF genes and super enhancers in tumor cells. The expression patterns of USF genes and chromatin interactions between USF genes and the super-enhancer were reversed via super-enhancer CRISPR-Cas9 knock-out, thus reversing malignant phenotypes of tumor cells in vitro and in vivo.
Conclusions
Overall, we identify that HPV integration remodels chromatin interactions between USFs and super enhancers to promote malignant phenotypes in HPV-related carcinoma, which provides insight into the three-dimensional mechanism in HPV-related carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. CAO.
Funding
National Key R&D Program of China (21YFC2701201) and the National Natural Science Foundation of China (82072895, 82141106, and 82203453).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11